Reconsidering postoperative basal infusion for opioid-sparing analgesia after total knee arthroplasty

Article information

Korean J Anesthesiol. 2026;79(2):131-132
Publication date (electronic) : 2026 March 17
doi : https://doi.org/10.4097/kja.26212
1Department of Medical Science, Chungnam National University School of Medicine, Daejeon, Korea
2Department of Anesthesiology and Pain Medicine, Chungnam National University School of Medicine, Daejeon, Korea
Corresponding author: Woosuk Chung, M.D., Ph.D. Department of Anesthesiology and Pain Medicine, Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu, Daejeon 35015, Korea Tel: +82-42-280-7840 Fax: +82-42-280-7968 Email: woosuk119@cnu.ac.kr
Received 2026 February 28; Accepted 2026 March 8.

Total knee arthroplasty (TKA) remains one of the most painful orthopedic procedures. Consequently, perioperative management of TKA has become a critical clinical issue, given that management of early postoperative pain is closely linked to mobilization, rehabilitation trajectory, and overall recovery. For decades, opioids have been the principal analgesic agents applied for perioperative pain management, but the limitations of opioid-based analgesics have raised several concerns. Beyond well-recognized adverse effects, such as postoperative nausea and vomiting, sedation, ileus, and respiratory depression, the broader public health implications of perioperative opioid exposure have become increasingly evident in the context of the global opioid crisis. These concerns have prompted increased efforts to minimize perioperative opioid use, while maintaining effective analgesia [1].

Previous studies have suggested that opioid-sparing approaches could reduce opioid consumption and lead to fewer opioid-related adverse effects, yet with comparable postoperative pain scores [2]. Thus, multimodal protocols incorporating various non-opioid analgesics (acetaminophen, non-steroidal anti-inflammatory drugs, ketamine, and α2-agonists) and appropriate peripheral nerve blocks have become increasingly common. In line with recent developments, in this issue of the Korean Journal of Anesthesiology, Han et al. have reported a randomized, double-blind, non-inferiority trial comparing opioid-based versus opioid-sparing patient-controlled analgesia (PCA) after TKA [3]. The investigators examined a clinically important question: whether continuous infusion of non-opioid agents can replace basal opioid infusion, without compromising postoperative analgesia.

The main contribution of this study was the direct comparison of basal PCA by infusion of fentanyl and ketorolac plus nefopam, while maintaining an identical fentanyl bolus access in both groups. The primary outcome, i.e., pain at rest on postoperative day 1, met the predefined criteria for non-inferiority within a clinically justified margin. Another important finding was a substantial reduction in the total opioid exposure, which decreased by approximately 55% in the opioid-sparing group. This reduction was accompanied by a significantly lower incidence of postoperative nausea and vomiting (12.2% vs. 34.7%). These findings provide clinically meaningful evidence that opioid consumption and opioid-related adverse effects can be reduced without compromising postoperative analgesia by replacing continuous infusion of opioids with that of non-opioid analgesics. Clinically, these results support reconsideration of the routine use of continuous basal opioid infusion for early postoperative pain control after TKA.

Although these results are consistent with those of recent publications, several points should be considered when interpreting these findings. First, the postoperative day 1 pain scores were relatively high in both groups. Although this likely reflects the painful nature of TKA, it raises the question of whether analgesia should be fully optimized. Non-inferiority does not necessarily indicate optimal analgesic adequacy. Although the authors explained the rationale for not including peripheral nerve blocks in their study protocol, this omission may limit generalizability of their results to enhanced recovery programs that routinely integrate regional strategies. The inclusion of nerve blocks may have reduced the overall pain intensity and could potentially have altered the between-group differences. Second, both study arms incorporated continuous basal infusion for postoperative pain control. However, current analgesic recommendations already discourage routine basal opioid infusions in favor of PCA of bolus medication [4]. There is also strong evidence that support multimodal analgesia with scheduled non-opioid agents [5]. In this context, a comparison between basal infusion strategies and structured, scheduled non-opioid regimens would further help to clarify whether basal infusion is necessary in modern multimodal analgesic practices.

Despite these considerations, their findings support the avoidance of routine basal opioid infusions via PCA devices. The evolution of perioperative analgesia does not require the elimination of opioids, but rather defines their appropriate role within multimodal strategies. By showing that similar levels of pain control can be achieved, with fewer complications, by using continuous infusion of non-opioid analgesics, this study adds an important perspective to current clinical practice.

Notes

Funding

None.

Conflicts of Interest

Woosuk Chung has been an editorial board for the Korean Journal of Anesthesiology. There were no other potential conflicts of interest relevant to this article.

References

1. Wu CL, King AB, Geiger TM, Grant MC, Grocott MP, Gupta R, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on perioperative opioid minimization in opioid-naïve patients. Anesth Analg 2019;129:567–77. 10.1213/ANE.0000000000004194. 31082966.
2. Kumar K, Kirksey MA, Duong S, Wu CL. A review of opioid-sparing modalities in perioperative pain management: methods to decrease opioid use postoperatively. Anesth Analg 2017;125:1749–60. 10.1213/ANE.0000000000002497. 29049119.
3. Han J, Jung H, Kim MK, Park YB, Min S. Opioid-based versus opioid-sparing patient-controlled analgesia using ketorolac and nefopam after total knee arthroplasty: a randomized, double-blind, non-inferiority trial. Korean J Anesthesiol 2026;79:213–23. 10.4097/kja.25695. 41630545.
4. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain 2016;17:131–57. 10.1016/j.jpain.2015.12.008. 26827847.
5. Hong B, Chung W, Oh C. Balancing benefit and risk: clinical considerations in the use of acetaminophen, non-steroidal anti-inflammatory drugs, and dexamethasone for perioperative multimodal analgesia. Korean J Pain 2025;38:364–77. 10.3344/kjp.25068. 40527754.

Article information Continued